A detailed history of Israel Englander (Millennium Management LLC) transactions in Glycomimetics Inc stock. As of the latest transaction made, Millennium Management LLC holds 746,954 shares of GLYC stock, worth $246,494. This represents 0.0% of its overall portfolio holdings.

Number of Shares
746,954
Previous 38,888 1820.78%
Holding current value
$246,494
Previous $91,000 2361.54%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.55 - $3.49 $1.81 Million - $2.47 Million
708,066 Added 1820.78%
746,954 $2.24 Million
Q4 2023

Feb 14, 2024

SELL
$1.13 - $2.54 $43,969 - $98,833
-38,911 Reduced 50.01%
38,888 $91,000
Q2 2023

Aug 14, 2023

SELL
$1.21 - $2.08 $498,512 - $856,947
-411,994 Reduced 84.12%
77,799 $135,000
Q1 2023

May 15, 2023

SELL
$1.25 - $4.05 $541,325 - $1.75 Million
-433,060 Reduced 46.93%
489,793 $617,000
Q4 2022

Feb 14, 2023

BUY
$0.67 - $3.03 $372,922 - $1.69 Million
556,601 Added 151.97%
922,853 $2.8 Million
Q3 2022

Nov 14, 2022

SELL
$0.56 - $0.9 $38,305 - $61,562
-68,403 Reduced 15.74%
366,252 $202,000
Q2 2022

Aug 15, 2022

BUY
$0.54 - $1.15 $16,451 - $35,035
30,466 Added 7.54%
434,655 $260,000
Q1 2022

May 16, 2022

SELL
$1.0 - $1.58 $287,524 - $454,287
-287,524 Reduced 41.57%
404,189 $461,000
Q4 2021

Feb 14, 2022

BUY
$1.44 - $2.14 $350,932 - $521,524
243,703 Added 54.4%
691,713 $996,000
Q3 2021

Nov 15, 2021

SELL
$1.8 - $2.39 $429,420 - $570,175
-238,567 Reduced 34.75%
448,010 $981,000
Q2 2021

Aug 16, 2021

BUY
$2.16 - $3.18 $1.38 Million - $2.03 Million
636,986 Added 1284.48%
686,577 $1.59 Million
Q1 2021

May 17, 2021

SELL
$2.89 - $4.22 $499,799 - $729,811
-172,941 Reduced 77.72%
49,591 $149,000
Q4 2020

Feb 16, 2021

BUY
$2.69 - $4.24 $598,611 - $943,535
222,532 New
222,532 $837,000
Q3 2020

Nov 16, 2020

SELL
$3.07 - $5.0 $404,632 - $659,010
-131,802 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$2.06 - $3.76 $53,514 - $97,677
25,978 Added 24.55%
131,802 $496,000
Q1 2020

May 14, 2020

BUY
$1.83 - $5.41 $50,577 - $149,521
27,638 Added 35.35%
105,824 $241,000
Q4 2019

Feb 14, 2020

SELL
$4.03 - $6.5 $617,549 - $996,047
-153,238 Reduced 66.22%
78,186 $414,000
Q3 2019

Nov 14, 2019

BUY
$2.8 - $12.85 $553,991 - $2.54 Million
197,854 Added 589.38%
231,424 $997,000
Q2 2019

Aug 15, 2019

BUY
$10.6 - $13.12 $189,803 - $234,926
17,906 Added 114.31%
33,570 $400,000
Q2 2019

Aug 14, 2019

SELL
$10.6 - $13.12 $27,538 - $34,085
-2,598 Reduced 14.23%
15,664 $374,000
Q1 2019

May 14, 2019

SELL
$9.96 - $13.44 $51,483 - $69,471
-5,169 Reduced 22.06%
18,262 $228,000
Q4 2018

Feb 14, 2019

BUY
$8.47 - $14.71 $198,460 - $344,670
23,431 New
23,431 $222,000
Q3 2018

Nov 14, 2018

SELL
$13.7 - $17.12 $1.8 Million - $2.25 Million
-131,231 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$14.63 - $19.19 $1.54 Million - $2.02 Million
-105,403 Reduced 44.54%
131,231 $2.12 Million
Q1 2018

May 15, 2018

BUY
$16.06 - $25.35 $3.59 Million - $5.66 Million
223,461 Added 1696.36%
236,634 $3.84 Million
Q4 2017

Feb 14, 2018

SELL
$10.51 - $17.22 $7.06 Million - $11.6 Million
-671,832 Reduced 98.08%
13,173 $221,000
Q3 2017

Nov 14, 2017

BUY
$10.14 - $14.85 $6.95 Million - $10.2 Million
685,005
685,005 $9.58 Million

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $17.3M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.